Pepric Appoints Dr. Enrico Bastianelli as Independent Director
News May 27, 2015
The General Assembly of Pepric has appointed Dr. Enrico Bastianelli as independent non-executive Board member. Dr. Bastianelli is the CEO of Bone Therapeutics since 2006, a cell therapy company for bone fracture repair and prevention.
Previously, Dr. Bastianelli gained a tremendous expertise in the cell and pharmaceutical industry based on many years of experience at Procter and Gamble Pharmaceuticals, McKinsey & Co and ProSkelia.
“We are delighted to welcome Dr. Bastianelli to the Board of Pepric, developing instrumentation for cell and particle detection and imaging. His experience and profound understanding of the end-users market of Pepric’s technology will deliver substantial benefit in the decision making process.”, said Stephanie Teughels, CEO of Pepric.
Commenting on his appointment, Dr. Bastianelli said: “I’m pleased to join Pepric offering new solutions for targeted molecular imaging and longitudinal cell detection. I’m looking forward to contribute to its business strategy to maximize the potential of its innovative instruments.”
Machine Learning to Increase the Pace of Brain Imaging AnalysisNews
New approach could allow doctors or researchers to quickly identify the data they need, and then rapidly fill in the fine details, making the process faster and more accurate.READ MORE
First Ever Online Event Focused on Cannabis ScienceNews
Analytical Cannabis is pleased to announce that the final line-up of speakers for the first ever cannabis science online event, The Science of Cannabis 2017 has been confirmed.READ MORE
Sharpest Image of Alzheimer’s Fibrils Shows Previously Unknown DetailsNews
The fibrils of the body's own amyloid beta (Aβ) protein are the main constituent of Alzheimer's disease-related and characteristic pathological protein deposits in the brain.READ MORE